# Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

> **NCT00588666** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 51 (actual)

## Conditions studied

- Myeloproliferative Disorder
- Urothelial Carcinoma
- Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00588666
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2016-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00588666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00588666, "Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00588666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*